Conformational Adaption May Explain the Slow Dissociation Kinetics of Roniciclib (BAY 1000394), a Type I CDK Inhibitor with Kinetic Selectivity for CDK2 and CDK9.
Ayaz, P., Andres, D., Kwiatkowski, D.A., Kolbe, C.C., Lienau, P., Siemeister, G., Lucking, U., Stegmann, C.M.(2016) ACS Chem Biol 11: 1710-1719
- PubMed: 27090615 
- DOI: 10.1021/acschembio.6b00074
- Primary Citation of Related Structures:  
5IF1, 5IEY, 5IEV, 5IEX - PubMed Abstract: 
Roniciclib (BAY 1000394) is a type I pan-CDK (cyclin-dependent kinase) inhibitor which has revealed potent efficacy in xenograft cancer models. Here, we show that roniciclib displays prolonged residence times on CDK2 and CDK9, whereas residence times on ...